Cargando…

Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents

INTRODUCTION: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been posing a severe threat to global public health. Although broadly neutralizing antibodies have been used to prevent or treat corona virus disease 2019 (COVID-19), new emerging variants have been pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zheng, Li, Dan, Chen, Yulu, Sun, Yeping, Jin, Changzhong, Hu, Caiqin, Feng, Yi, Su, Junwei, Ren, Li, Hao, Yanling, Wang, Shuo, Zhu, Meiling, Liu, Ying, Qi, Jianxun, Zhu, Biao, Shao, Yiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207940/ https://www.ncbi.nlm.nih.gov/pubmed/37234155 http://dx.doi.org/10.3389/fimmu.2023.1160283

Ejemplares similares

Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
por: Hu, Caiqin, et al.
Publicado: (2022)

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
por: Zhou, Yunjiao, et al.
Publicado: (2021)

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant
por: Yuan, Mengqi, et al.
Publicado: (2023)

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies
por: Ding, Chengchao, et al.
Publicado: (2021)

High Heterogeneity of Virus-Neutralizing and RBD-Binding Activities of COVID-19 Convalescent Sera
por: Astakhova, E. A., et al.
Publicado: (2022)

Neutralizing antibodies in convalescent patients
por: Uhl, Lion F. K., et al.
Publicado: (2020)

Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
por: Hu, Caiqin, et al.
Publicado: (2022)

Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
por: Ma, Hang, et al.
Publicado: (2022)

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
por: Yue, Shuai, et al.
Publicado: (2021)

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants
por: Xu, Hua, et al.
Publicado: (2021)

Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection
por: Mu, Song, et al.
Publicado: (2022)

A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
por: Yuan, Mengqi, et al.
Publicado: (2022)

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants
por: Lin, Wei-Shuo, et al.
Publicado: (2021)

Mutational escape prevention by combination of four neutralizing antibodies that target RBD conserved regions and stem helix
por: Tang, Haoneng, et al.
Publicado: (2022)

The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum
por: Lu, Lu, et al.
Publicado: (2021)

Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor
por: Ju, Bin, et al.
Publicado: (2018)

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents
por: Cao, Yunlong, et al.
Publicado: (2022)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
por: Hu, Jie, et al.
Publicado: (2021)

Immunity Induced by Inactivated SARS-CoV-2 Vaccine: Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort
por: Chen, Ying, et al.
Publicado: (2023)

Detection and analysis of variants of JC polyomavirus in urine samples from HIV-1-infected patients in China’s Zhejiang Province
por: Hu, Caiqin, et al.
Publicado: (2018)

A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
por: Liu, Shuo, et al.
Publicado: (2022)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

Antibodies Produced Toward Recombinant RBD and Nucleocapsid Neutralize SARS-COV-2
por: Rezaei, Amir, et al.
Publicado: (2022)

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
por: Tolbert, William D., et al.
Publicado: (2023)

Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants
por: Chang, Matthew R., et al.
Publicado: (2022)

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19
por: Kaku, Yu, et al.
Publicado: (2021)

Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum
por: Liang, Dan, et al.
Publicado: (2022)

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
por: Luo, Deyan, et al.
Publicado: (2022)

High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern
por: Li, Maggie, et al.
Publicado: (2022)

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
por: Yi, Chunyan, et al.
Publicado: (2021)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant
por: Jia, Lina, et al.
Publicado: (2021)

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
por: Chi, Xiaojing, et al.
Publicado: (2022)

hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants
por: Liu, Junli, et al.
Publicado: (2021)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

Changes in Serum Neutralizing Antibodies Levels During Convalescence of COVID-19 Patients
por: Chen, Qing-Qing, et al.
Publicado: (2022)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding
por: Long, Yingyi, et al.
Publicado: (2021)

The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD
por: Greaney, Allison J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rj3b3sl2vss4cihvlvdmtfl3gi